Technical & News Articles about Deargen
PROTAC is known as a new platform for disease treatment that has been difficult to reach with existing biopharmaceuticals. Deargen is accelerating the development of drugs through PROTAC by rapidly and precisely searching for small molecules that can bind to the target protein.
Read More
The study of colorectal cancer has shown that MERTK (TYRO3 / AXL / MER, TAM receptor kinase family) is an important target for cancer cell immune response evasion mechanism. Thus, Deargen is researching by focusing on small molecule inhibitors.
Read More
ALS treatments that currently are being used under FDA approval have a level that relieves symptoms and slows the progression of Lou Gehrig. Deargen is challenging the development of new ALS treatments by reducing TDP-43 protein aggregation observed in more than 90% of patients with Lou Gehrig.
Read More
Uppthera Inc. that is a domestic PROTAC-based drug development company joined hands with Deargen Inc. that is an AI-based drug development platform company. It is going to discover PROTAC drug candidates using artificial intelligence technology. On the 7th, Uppthera Inc. and Deargen Inc. recently announced that they have signed a strategic technology partnership agreement on the AI-based PROTAC drug development.
Read More
We introduce DEARGEN’s research results on the model that predicts the primary cancer sites (cancer metastasis prediction) through the gene expression profile (GEP).
Read More
Deargen has announced the research results on an AI technology CWx that can discover biomarkers on disease prognosis. The research achievements has been published in the journal Frontiers in Genetics.
Read More
Deargen has announced research results on an AI technology Wx that can discover novel biomarkers. Research achievements are being published in the journal of the Nature Scientific Report, and two inventions related to these have been patented.
Read More
Deargen was selected for the TIPS program, so it will receive a total of $600,000 in R & D expenses from the operator Medytox Venture Investment.
Read More
Deargen launches a beta service of ‘DearTRANS’ that is a cloud-based genomic big data analysis platform that the world’s first artificial intelligence technologies are applied.
Read More
Deargen has been selected for the 2017 National Program for Cancer Control that is hosted by the Ministry of Health and Welfare and the National Cancer Center. Deargen will develop an integrated prognostic analysis model of lung cancer using artificial intelligence by collaboration with St. Mary’s Hospital and Dankook University.
Read More